Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis.

Epstein-Barr Virus (EBV) contributes to the development of lymphoid and epithelial malignancies. While EBV's latent phase is more commonly associated with EBV-associated malignancies, there is increasing evidence that EBV's lytic phase plays a role in EBV-mediated oncogenesis. The lytic phase contributes to oncogenesis primarily in two ways: (1) the production of infectious particles to infect more cells, and (2) the regulation of cellular oncogenic pathways, both cell autonomously and non-cell autonomously. The production of infectious particles requires the completion of the lytic phase. However, the regulation of cellular oncogenic pathways can be mediated by an incomplete (abortive) lytic phase, in which early lytic gene products contribute substantially, whereas late lytic products are largely dispensable. In this review, we discuss the evidence of EBV's lytic phase contributing to oncogenesis and the role it plays in tumor formation and progression, as well as summarize known mechanisms by which EBV lytic products regulate oncogenic pathways. Understanding the contribution of EBV's lytic phase to oncogenesis will help design ways to target it to treat EBV-associated malignancies.